Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial

NCT04636034 is registered in ClinicalTrials.gov with University Hospital Bispebjerg and Frederiksberg as lead sponsor.

NCT NCT04636034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04636034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Ganglion Sphenopalatine Block (SPG-block) Versus Placebo on Persistent Headache Following COVID-19 Infection: a Randomised, Blinded, Clinical Trial
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Phase
Phase 3
Overall status
Terminated
Start date
January 12, 2021
Completion date
June 6, 2022
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, headache, persistent headache following covid-19, sphenopalatine ganglion block